Showing 2630 results
- https://www.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patientsEXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…
- https://www.novartis.com/news/media-releases/new-novartis-data-presented-ectrims-show-benefit-gilenya-patient-disability-progression-10-yearsACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those…
- https://www.novartis.com/news/media-releases/novartis-presents-new-positive-data-ehmtic-showing-amg-334-significantly-reduces-monthly-migraine-days-chronic-migraineDetailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine…
- https://www.novartis.com/news/media-releases/novartis-foundation-showcases-progress-leprosy-elimination-programs-19th-international-leprosy-congressEmerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries Retrospective…
- https://www.novartis.com/news/media-releases/new-novartis-point-care-nijitm-system-may-provide-earlier-diagnosis-severe-allergic-asthma-and-faster-treatment-decisionsNijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…
- https://www.novartis.com/news/media-releases/alcon-launches-ngenuity-3d-visualization-system-designed-further-enhance-retinal-surgeon-experienceHeads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1] Offers enhanced 3D visualization with high-definition resolution, image…
- https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-consistently-more-effective-seretide-reducing-copd-flare-ups-across-different-patient-groupsUltibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered…
- https://www.novartis.com/news/media-releases/airflusal-forspiro-showed-superiority-12-months-over-seretide-diskus1-persistence-treatmentNew study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving…
- https://www.novartis.com/research-development/research-disease-areas/oncology-research-novartis
- https://www.novartis.com/news/media-releases/novartis-new-data-reinforces-superiority-cosentyx-versus-stelara-achieving-skin-clearance-psoriasis-patientsResults from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page